Protein expression

By replacing the low-frequency codon with high-frequency synonyms in the target nucleic acid sequence, the problem of low-efficiency expression efficiency in host cells is solved, and an efficient and continuous expression effect in iPSC is achieved.

CN118946664APending Publication Date: 2024-11-12CAMBRIDGE ENTERPRISE LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202280090489.9
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2021-12-06
Filing Date
2022-12-06
Publication Date
2024-11-12

AI Technical Summary

Technical Problem

The prior art is difficult to effectively express the target nucleic acid sequence in host cells, especially in human induced pluripotent stem cells (iPSCs), resulting in inefficient and instability of gene editing.

Method used

Codon optimization is performed on the target nucleic acid sequence by replacing the codon usage frequency of the highly expressed protein gene in the host cell or the codon usage frequency from the highly expressed protein gene in the same species, and the codon usage frequency of the low frequency is high Frequently use synonymous codons to improve expression efficiency.

Benefits of technology

The expression efficiency and sustainability of target nucleic acids in host cells was significantly improved, especially in iPSCs and their differentiated cell lines, improving the expression of Cas9 protein and the application potential of the CRISPR-Cas system.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118946664A_ABST
    Figure CN118946664A_ABST
Patent Text Reader

Abstract

The present invention relates to a method for codon optimization of a target nucleic acid sequence for expression in a host cell. The invention also relates to codon optimized nucleic acids for improving expression in host cells, as well as vectors and host cells comprising codon optimized nucleic acids.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to a method for codon-optimizing a target nucleic acid sequence for expression in a host cell. The present invention also relates to codon-optimized nucleic acids for improving expression in a host cell, and vectors and host cells comprising codon-optimized nucleic acids. Background Art

[0002] Codon is a three-nucleotide sequence of DNA or RNA, which encodes a specific amino acid or sends a signal for translation termination ("termination / stop" codon). Degeneracy exists in the genetic code because the codon sequence present is more than amino acids or termination codons. In fact, 18 of the 20 common amino acids are encoded by multiple "synonymous codons" (i.e., different codons encoding the same amino acid). The use of codons between species can be significantly different: different species typically show "bias" to certain codons, and some species only rarely use or do not use specific codons at all. When the target gene contains codons that are rarely used by the host, the gene encounters translation stagnation in the cell from the host, thereby reducing expression efficiency or preventing expression completely. The codon optimization method takes into account the differences in codon bias between species, and is designed to improve the codon composition of the target nucleic acid sequence by replacing the codons that are rarely used by the host with synonymous codons that are used with higher frequency by the host and are therefore "preferred" by the host.

[0003] Recently, codon usage has come into focus as a key determinant of translation elongation rate and co-translational protein folding, with host-preferred codons improving translation efficiency and folding fidelity. From yeast to humans, the unequal use of synonymous codons (known as "codon bias") and the universal nature of this bias suggest the existence of a secondary code within the more familiar genetic code. This secondary code emerges as a major regulator of translation rate and co-translational protein folding and therefore as an important determinant of cellular levels of a particular protein.

[0004] In order to identify the codon bias of a specific host, the frequency of codon usage is typically determined in hundreds or thousands of coding DNA sequences (CDS). In order to codon optimize the target gene, the codons (which may be referred to as "non-preferred codons") present at low frequencies (or not present at all) in the host within the gene are replaced with synonymous codons (which may be referred to as "preferred codons") more commonly used by the host. Codon optimization is intended to improve the expression efficiency of the target gene without changing the sequence of the encoded protein.

[0005] Although well-established codon optimization methods are known in the art, expression of some genes remains challenging, and in some cases, codon-optimized genes do not achieve sufficiently high expression levels or fail to maintain adequate expression levels over time.

[0006] For example, human induced pluripotent stem cells (hiPSC / iPSC) represent a powerful research tool with the potential to differentiate into a variety of cell types. However, the application of these cells in genome-wide genetic screening using the CRISPR (clustered regularly interspaced short palindromic repeats)-Cas (CRISPR-associated protein) gene editing system has been hampered by the inability of these cells to effectively express Cas proteins (e.g., Cas9), although the genes encoding these proteins are codon-optimized for expression in human cell lines. The mechanism by which Cas genes are silenced in differentiated cell types derived from iPSCs is currently unknown.

[0007] There is an urgent and unmet need for improved codon optimization methods that enable efficient expression of target nucleic acid sequences in host cells. Summary of the invention

[0008] The inventors have developed a novel method for codon optimization of target nucleic acid sequences for expression in host cells. According to the present invention, codon optimization utilizes the codon usage frequency of genes encoding proteins highly expressed by host cells or the codon usage frequency of genes encoding proteins highly expressed in cells from the same species as the host cell. Codons used at low frequencies in genes encoding highly expressed proteins in target nucleic acids are replaced with synonymous codons used at high frequencies in genes encoding highly expressed proteins.

[0009] The current " gold standard " that is used for target nucleic acid to be carried out to codon optimized is based on the codon bias of the species level that is derived from hundreds or thousands of encoding sequences.Unexpectedly, the inventors have found that, compared with the corresponding nucleic acid that uses the current gold standard to optimize, the codon bias of the proteinaceous gene of the high expression of coding is carried out to target nucleic acid sequence to codon optimized and has significantly improved expression efficiency.Codon optimized according to the present invention has realized high-level and continuous expression, even in the cell type that typically does not express the gene that comprises the nucleotide sequence based on codon optimized.

[0010] Importantly, codon optimization according to the present invention achieves high-level and sustained protein expression in iPSCs and differentiated cell lines derived from iPSCs, which significantly improves the potential applications of these cells in research.

[0011] The present invention provides a method for codon-optimizing a target nucleic acid sequence for expression in a host cell, the method comprising changing the codon usage frequency of the target nucleic acid sequence based on the codon usage frequency of a gene encoding a protein that is highly expressed in the host cell or the codon usage frequency of a gene encoding a protein that is highly expressed in cells from the same species as the host cell.

[0012] In some embodiments, the method comprises replacing one or more non-preferred codons within the target nucleic acid sequence with preferred synonymous codons, wherein: (a) the non-preferred codons are codons used at a low frequency by the gene encoding the highly expressed protein; and (b) the preferred codons are codons used at a high frequency by the gene encoding the highly expressed protein.

[0013] In some embodiments, a non-preferred codon is a codon that is used by the gene encoding the highly expressed protein at a lower frequency than would be expected if each synonymous codon were used randomly.

[0014] In some embodiments, the gene encoding the highly expressed protein uses non-preferred codons at a frequency of less than 50%, less than 45%, less than 40%, less than 35%, less than 33%, less than 30%, less than 25%, less than 20%, less than 16%, less than 15%, less than 10%, less than 5%, or 0%.

[0015] In some embodiments, a preferred codon is a codon that is used by the gene encoding the highly expressed protein at a higher frequency than would be expected if each synonymous codon were used randomly.

[0016] In some embodiments, the gene encoding the highly expressed protein uses preferred codons at a frequency of at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or 100%.

[0017] In some embodiments, the method comprises replacing at least 25%, at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or 100% of the non-preferred codons in the target nucleic acid with preferred synonymous codons.

[0018] In some embodiments, the method comprises replacing all non-preferred codons used at a frequency of 0% in the gene encoding the highly expressed protein within the target nucleic acid with preferred synonymous codons.

[0019] In some embodiments, the method comprises replacing all non-preferred codons with preferred synonymous codons in the region of the target nucleic acid encoding the N-terminal region of the protein.

[0020] In some embodiments, the method comprises replacing all non-preferred codons in the 5' region of the target nucleic acid (optionally the first at least 100, at least 200, at least 300, at least 400, at least 500, at least 600, at least 700, at least 800, at least 900, or at least 1000 codons from the 5' end of the target nucleic acid) with preferred synonymous codons.

[0021] In some embodiments, the highly expressed protein is a housekeeping protein or a cell marker protein. In some embodiments, the highly expressed protein is selected from GAPDH, β-tubulin, β-actin and tubulin III. In some embodiments, the highly expressed protein is tubulin III.

[0022] In some embodiments, the one or more non-preferred codons are selected from: alanine codons GCA, GCG, and GCT; arginine codons AGA and CGT; cysteine ​​codon TGT; glutamine codon CAA; isoleucine codon ATA; leucine codons CTA and TTA; lysine codon AAA; proline codon CCG; serine codon TCC; threonine codons ACA, ACG, and ACT; tyrosine codon TAT; valine codons GTA and GTT; and stop codons TAA and TAG.

[0023] In some embodiments, the one or more non-preferred codons are selected from: asparagine codon AAT; aspartate codon GAT; glutamate codon GAA; glycine codons GGA, GGG and GGT; histidine codon CAC; isoleucine codon ATT; leucine codons CTC, CTT and TTG; phenylalanine codon TTT; proline codon CCA; serine codons TCA and TCG; and valine codon GTC.

[0024] In some embodiments, the preferred codon is selected from: the alanine codon GCC; the cysteine ​​codon TGC; the glutamine codon CAG; the lysine codon AAG; the threonine codon ACC; the tyrosine codon TAC; and the stop codon TGA.

[0025] In some embodiments, the preferred codons are selected from: the arginine codons AGG, CGA, CGC, and CGG; the asparagine codon AAC; the aspartate codon GAC; the glutamate codon GAG; the glycine codon GGC; the histidine codon CAT; the isoleucine codon ATC; the leucine codon CTG; the phenylalanine codon TTC; the proline codons CCC and CCT; the serine codons AGC, AGT, and TCT; and the valine codon GTG.

[0026] In some embodiments, the host cell is selected from human cells, bacterial cells, yeast cells and fungal cells. In some embodiments, the host cell is a human cell. In some embodiments, the host cell is a HEK293 cell. In some embodiments, the host cell is a human induced pluripotent stem cell (iPSC). In some embodiments, the host cell is a differentiated cell derived from iPSC, optionally wherein the host cell is selected from iPSC-derived neurons such as cortical neurons, dopaminergic neurons or motor neurons, iPSC-derived macrophages, iPSC-derived cardiomyocytes, and iPSC-derived hepatocytes.

[0027] In some embodiments, the target nucleic acid encodes a Cas protein, optionally wherein the Cas protein is selected from Cas9, Cas12a, and Cas13Rx.

[0028] The present invention also provides a nucleic acid comprising a nucleic acid sequence that has been codon-optimized by the method of the present invention.

[0029] The present invention also provides a codon-optimized nucleic acid for improving expression in a host cell, wherein the codon usage frequency of the nucleic acid corresponds to the codon usage frequency of a gene encoding a protein highly expressed by the host cell or the codon usage frequency of a gene encoding a protein highly expressed in cells from the same species as the host cell.

[0030] In some embodiments, the codon-optimized nucleic acid comprises a lower frequency of non-preferred codons compared to a non-optimized nucleic acid sequence encoding the same amino acid sequence.

[0031] In some embodiments, the codon-optimized nucleic acid comprises a higher frequency of preferred codons compared to a non-optimized nucleic acid sequence encoding the same amino acid sequence.

[0032] The present invention also provides a nucleic acid encoding Cas9 and comprising a nucleic acid sequence having at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or 100% sequence identity to SEQ ID NO: 1 or SEQ ID NO: 3.

[0033] The present invention also provides a nucleic acid encoding Cas12a and comprising a nucleic acid sequence having at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or 100% sequence identity to SEQ ID NO:4.

[0034] The present invention also provides a nucleic acid encoding Cas13Rx and comprising a nucleic acid sequence having at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or 100% sequence identity to SEQ ID NO:5.

[0035] The present invention also provides a vector comprising the nucleic acid according to the present invention.

[0036] The present invention also provides a host cell comprising the nucleic acid according to the present invention or the vector according to the present invention.

[0037] In some embodiments, the host cell is selected from human cells, bacterial cells, yeast cells and fungal cells. In some embodiments, the host cell is a human cell. In some embodiments, the host cell is a HEK293 cell. In some embodiments, the host cell is a human induced pluripotent stem cell (iPSC). In some embodiments, the host cell is a differentiated cell derived from iPSC, optionally wherein the host cell is selected from iPSC-derived neurons such as cortical neurons, dopaminergic neurons or motor neurons, iPSC-derived macrophages, iPSC-derived cardiomyocytes, and iPSC-derived hepatocytes. BRIEF DESCRIPTION OF THE DRAWINGS

[0038] Figure 1 .(A) Schematic diagram of the PiggyBac (PB) transposon plasmid containing the starting Cas9 (old-Cas9) sequence. (B) Cas9 and (C) GAPDH (glyceraldehyde-3-phosphate dehydrogenase) mRNA levels in iPSC Cas9 cells at 0 days (iPSC), 10 days, and 20 days during differentiation into dopaminergic neurons. By day 20, Cas9 mRNA decreased by about 60%.

[0039] Figure 2 (A) Schematic diagram showing homology-directed recombination for knocking in Cas9 upstream of GAPDH. (B) Levels of Cas9 and GAPDH mRNA in GapdhCas9-iNgn2 iPSCs during differentiation of iPSCs into neurons. (C) Levels of GAPDH mRNA in GapdhCas9 and WT (no Cas9) iNgn2 cells during differentiation of iPSCs into neurons.

[0040] Figure 3.(A) Western blot showing Cas9 and GAPDH protein expression during iPSC differentiation into neurons. (B) Densitometry quantification of Cas9 protein levels from (A) in Bob-iNgn2 Gapdh-Cas9 cells during differentiation into neurons. (C) Schematic diagram of the fluorescent reporter constructs used. (D) Flow cytometry plot showing dual fluorescence of the reporter construct (left) and loss of GFP fluorescence when Cas9 is present (right). (E) Cas9 cleavage efficiency quantified by loss of GFP fluorescent reporter 4 days after reporter transduction.

[0041] Figure 4 (A) Cas9 protein expression in the presence of MG1 32 inhibitor to block proteasomal degradation or bafilomycin A1 (BafAl) to block the autophagy-lysosomal pathway. (B) Cas9 protein expression in different media compositions. DMEM = Dulbecco's modified Eagle's medium; NEAA = non-essential amino acids.

[0042] Figure 5 Comparison between bacterial (E. coli) codon usage frequency (black bars) and human universal codon usage frequency (grey bars). Dashed boxes indicate codons with significant differences in usage frequency between humans and bacteria.

[0043] Figure 6 Comparison between .old-Cas9 codon usage frequency (black bars) and human universal codon usage frequency (grey bars). Solid boxes indicate optimized codons, and dashed boxes indicate randomly distributed codons.

[0044] Figure 7 Comparison between tubulin III codon usage frequency (black bars) and human universal codon usage frequency (grey bars). Dashed boxes indicate codons not used by tubulin III; and triangles indicate codons that are more commonly used in tubulin III than in humans.

[0045] Figure 8 . Comparison between the codon usage frequency of codon-optimized Cas9 (CodOpt-Cas9; SEQ ID NO: 1) (black bars) and the universal codon usage frequency of humans (grey bars). Dashed boxes indicate codons not used by CodOpt-Cas9; and triangles indicate codons with higher usage in CodOpt-Cas9.

[0046] Fig. 9 .Schematic diagram of Old-Cas9 (left) and CodOpt-Cas9 (right) expression constructs.

[0047] Fig.10(A) Old-Cas9 and CodOpt-Cas9 mRNA levels in HEK293-Cas9 lines. (B) and (C) Old-Cas9 protein levels and CodOpt-Cas9 protein levels in HEK293 cells (B) and their quantification (C). (D) Cas9 editing efficiency in HEK293 cells using a reporter plasmid.

[0048] Fig.11 . Indel formation achieved by Cas9 directed editing of a non-essential gene (ST6GALNAC6) in HEK-Cas9 and control lines. The graph is a TIDE profile obtained by tracking indel formation on http: / / shinyapps.datacurators.nl / tide / . Y axis = sequence %.

[0049] Fig.12 (A) Old-Cas9 and CodOpt-Cas9 mRNA levels in Bob-iNgn2 Cas9 iPSC cells generated using PiggyBac. (B) and (C) Western blot of Old-Cas9 and CodOpt-Cas9 protein levels in Bob-iNgn2 iPSC cells and their quantification (C).

[0050] Fig.13 . Shown are Western blots and their relative quantification of Cas9 protein levels in O1d-Cas9 and CodOpt-Cas9 Bob-iNgn2 iPSC lines during different time points of differentiation into neurons.

[0051] Fig.14 .Schematic diagram of O1d-Cas9 (left), NOpt-Cas9 (middle), and CodOpt-Cas9 (right) expression constructs.

[0052] Fig.15 . Flow cytometry graphs showing loss of GFP reporter fluorescence in Bob-iNgn2 iPSCs with Old-Cas9, NOpt-Cas9 or CodOpt-Cas9. Editing efficiency of Cas9 variants was assessed during differentiation into neurons (iPSCs, day 4 and day 10).

[0053] Fig.16 Quantification of Cas9 cleavage efficiency achieved by Old-Cas9, NOpt-Cas9, CodOpt-Cas9, or no Cas9 (WT) in Bob-iNgn2 iPSCs and at different time points of neuronal differentiation. Highlighted boxes emphasize differences in Cas9 editing across protocols as neuronal differentiation progresses.

[0054] Fig.17 Cas9 mRNA (A) and protein (B) levels produced by Old-Cas9, CodOpt-Cas9, or NOpt-Cas9 in Bob-iNgn2 iPSCs and during differentiation into neurons. Protein level quantification is represented in (C) - the highlighted grey / black box emphasizes the differences in Cas9 levels with neuronal differentiation and maturation.

[0055] Fig.18 (A) Cas9 protein levels in iPSC-derived hepatocytes containing Old-Cas9 or CodOpt-Cas9. (B) Quantification shows higher levels of CodOpt Cas9 in day 10 differentiated hepatoblastoma cells (grey / black boxes).

[0056] Fig.19 Comparison between Cas12a codon usage frequency (black bars) and human universal codon usage frequency (grey bars). Dashed boxes indicate amino acids that are biased towards specific codons.

[0057] Fig. 20 .Comparison between the codon usage frequency of codon-optimized Cas12a (black bars) and the universal codon usage frequency of humans (grey bars).

[0058] Fig.21 Comparison between Cas13Rx codon usage frequency (black bars) and human universal codon usage frequency (grey bars).

[0059] Fig. 22 .Comparison between the codon usage frequency of codon-optimized Cas13Rx (black bars) and the universal codon usage frequency of humans (grey bars).

[0060] Fig.23 Schematic representation of a plasmid containing L1Dr optimized using the existing gold standard method based on human codon usage frequency (denoted "standard codon optimization") and using the codon bias of tubulin III as described herein (denoted "novel codon optimization").

[0061] Fig.24(A) Transfection efficiency of standard optimized and novel optimized plasmids in HEK293 and iPSC cells. (B) Western blot showing LlDr (c-Myc) and GAPDH protein expression in Bob-iNgn2 iPSC and HEK293 cells 5 days after transfection. (C) Densitometry quantification of LlDr (c-myc) levels from (B) relative to Gapdh levels in Bob-iNgn2 iPSC and HEK293 cells. The existing gold standard codon optimization method is denoted as "standard optimization" and the optimization method using codon bias for tubulin III is denoted as "novel optimization". DETAILED DESCRIPTION

[0062] The present invention is based on the unexpected discovery that by codon-optimizing a target nucleic acid sequence for expression in a host cell (or a cell from the same species as the host cell) based on the codon usage frequency of a gene encoding a protein that is highly expressed in a host cell (or the codon usage frequency of a gene encoding a protein that is highly expressed in a cell from the same species as the host cell), the expression of the target nucleic acid can be significantly improved. In particular, the inventors have found that this method achieves efficient and sustained expression of target nucleic acids that have previously been difficult to express (even when codon-optimized using the current gold standard of codon optimization based on species-level codon bias).

[0063] In many host cell types, transgenic expression is difficult.An example of a host cell that may be challenging for transgenic expression is a cell derived from human induced pluripotent stem cells (hiPSC / iPSC).iPSC represents a powerful research tool with the potential to differentiate into a variety of cell types, so it is highly desirable to improve the transgenic expression in such cells.In recent years, many hiPSC-based cell lines have been produced, which allow controlled and rapid differentiation into various cell types, including macrophages (immune cells), cardiomyocytes (muscle cells) and neurons (nerve cells).These cell lines have applications in a wide range of research fields.For example, hiPSC-derived neurons provide a powerful replacement for immortalized human cell lines and non-human primary neuronal cells for in vitro studies to understand neurodegenerative disorders, because they can be differentiated into specific neuronal subtypes found to be affected in these disorders.Several differentiation protocols have been optimized to produce specific neuronal subtypes (such as cortical neurons, dopaminergic neurons and even motor neurons), which can be robustly used to model Alzheimer's disease, Parkinson's disease or motor neuron disease, respectively.

[0064] Another powerful research tool is the CRISPR-Cas gene editing system, which has revolutionized molecular methods that help describe cellular mechanisms (e.g., mechanisms of neuronal degeneration). CRISPR-Cas9 genetic screening in multiple cell types is essential in identifying novel cellular pathways and genetic targets that may contribute to translational research. Although a large number of these studies rely on initiating whole genome screening at the iPSC / progenitor cell stage and extrapolating the findings to iPSC-derived cell types, CRISPR-Cas9 screening in differentiated cells has been challenging, mainly due to the inability to effectively express Cas9 in iPSC-derived cell lines. The mechanism of Cas9 inactivation in iPSC-derived differentiated cell types (including neurons) is currently unknown. The inability to effectively express this key component of the CRISPR-Cas9 system greatly limits the research potential of iPSC-derived cell types.

[0065] A variety of methods have been studied to try to overcome Cas9 silencing during iPSC differentiation. Such methods include using lentivirus / transposon to integrate multiple copies of Cas9 into the genome; testing Cas9 expression under different mammalian expression promoters; and targeting Cas9 to specific locations in the genome, such as genomic safe harbor sites. Despite these efforts, the Cas9 protein level in differentiated cells is significantly reduced compared to the level observed in iPSC. The inventors attempted to circumvent Cas9 silencing by inserting Cas9 at the site of the housekeeping gene (glycerol-3-phosphate dehydrogenase (GAPDH)) to help achieve sustained expression. Despite successful knock-in at the endogenous GAPDH gene, the promoter of the housekeeping gene could not maintain constitutive expression of Cas9 protein during differentiation into neuronal cell types. Interestingly, despite the reduction in protein levels, the mRNA level of Cas9 remained detectable during differentiation, indicating that transcription and translation have been uncoupled.

[0066] The Cas9 gene typically used in experimental studies ("old-Cas9" herein) is derived from Streptococcus pyogenes and is codon-optimized for expression in humans using human universal codon usage, which represents the current gold standard codon optimization method. Based on the uncoupling of Cas9 transcription and translation observed in iPSC-derived cell lines, the inventors hypothesized that Cas9 may require further codon optimization to function in differentiated cell types.

[0067] The inventors sought to identify whether genes highly expressed in iPSC-derived differentiated cells exhibit specific codon bias by comparing the codon usage frequency of tubulin III (Ensembl transcript: TUBB3-208ENST00000555576.5; SEQ ID NO: 8), a marker gene highly expressed in neuronal cells with a universal codon usage frequency in humans ( Figure 7 ). Universal codon usage in humans is typically derived from tens of thousands of human coding DNA sequences (CDS). As used herein, universal codon usage in humans is derived from the codon usage database provided by the Kazusa DNA Institute, which is based on the codon usage of 93,487 human CDSs (Nakamura, Y. et al. Nucleic aCids research [Nucleic acid research] 2000 28 (1): 292). Unless otherwise specified, references to codon "frequency of use in humans" or "universal codon usage in humans" herein refer to the codon usage frequencies described in the Homo sapiens codon usage table in the Kazusa codon usage database.

[0068] The inventors found that compared with the universal codon usage of people, tubulin III exhibits different codon biases for several codons. Unexpectedly, tubulin III does not use several codons commonly used in people, such as cysteine ​​codon TGT (46% usage frequency in people); Lysine residue AAA (43% usage frequency in people); And tyrosine residue TAT (44% usage frequency in people). In addition, tubulin III shows strict preference for the exclusive use of alanine codon GCC (40% usage frequency in people) and threonine codon ACC (36% usage frequency in people), although each of these amino acids has three other synonymous codons available. Tubulin III also shows a greater preference for specific codons, for example, tubulin III uses histidine residue CAT at a higher frequency (60% usage frequency) than CAC (40% usage frequency), while CAC is preferred in the universal codon usage of people (58% usage frequency). The inventors believe that the high expression levels achieved by tubulin III in neuronal cells are due to these codon biases facilitating efficient expression in these cell types.

[0069] The inventors exploited tubulin III codon bias to generate a codon-optimized version of Cas9 (CodOpt-Cas9) that more closely reflects the codon usage frequency of tubulin III. The CodOpt-Cas9 sequence obtained after these changes is represented by SEQ ID NO: 1:

[0070]

[0071] The starting Cas9 (old-Cas9) sequence is represented by SEQ ID NO: 2:

[0072]

[0073] Old-Cas9 is a commercially available Cas9 sequence that has been codon-optimized using universal codons for people. In order to use tubulin III codon usage frequency to perform codon optimization on this sequence, the inventors replaced 33% of the codons with tubulin III preferred synonymous codons (replacing 463 codons of the original Cas9 sequence). For example, 100% of the alanine, glutamine, lysine and tyrosine codons in CodOpt-Cas9 are provided by tubulin III preferred codons GCC, CAG, AAG and TAC respectively (in Old-Cas9, these codons are used with 93%, 96%, 77% and 87% frequency, respectively). In addition, the Old-Cas9 codons that are not used by tubulin III are replaced with tubulin III preferred codons, for example, lysine AAA codons are replaced with AAG, and tyrosine TAT codons are replaced with TAC.

[0074] To test whether CodOpt-Cas9 can be expressed, both Old-Cas9 and CodOpt-Cas9 were expressed in human embryonic kidney 293 (HEK293) cells. Unexpectedly, in HEK293 cells, CodOpt-Cas9 showed higher expression at both mRNA and protein levels compared to old-Cas9. These high levels of Cas9 help CodOpt-Cas9 HEK293 cells show higher nuclease activity and faster cutting efficiency compared to HEK293 cells containing old-Cas9. However, it should be noted that tubulin III is not highly expressed in HEK293 cells, so these results indicate that the codon bias of tubulin III is not unique to neurons.

[0075] Then, the inventors tested whether CodOpt-Cas9 can be easily expressed in iPSC. Similar to the results in HEK293 cells, CodOpt-Cas9 reached higher expression levels in iPSC compared to old-Cas9. As mentioned previously, old-Cas9 expression dropped sharply during the differentiation of iPSC into neuronal cell types, so the inventors next attempted to distinguish iPSC expressing CodOpt-Cas9. Advantageously, the inventors found that CodOpt-Cas9 was expressed throughout the differentiation of iPSC, and CodOpt-Cas9 remained detectable in differentiated neuronal cells, while old-Cas9 showed a sharp decrease in expression levels and eventually became undetectable as cells entered a more neuronal phenotype. These results confirm that codon optimization of Cas9 based on the codon bias of tubulin III achieves effective and sustained expression of Cas9 in iPSC-derived differentiated neurons.

[0076] In order to test whether the above-mentioned favorable results are limited to iPSC-derived neuronal cells, the inventors attempted to express CodOpt-Cas9 in iPSC-derived hepatocytes (which typically do not express tubulin III). Similar to iPSC-derived neuronal cells, old-Cas9 showed a sharp reduction in expression levels during hepatocyte differentiation, and CodOpt-Cas9 reached and maintained significantly higher expression levels throughout the differentiation. Advantageously, together with the increased expression observed in HEK293 cells, these results demonstrate that codon optimization of sequences based on the codon bias of tubulin III has achieved increased and sustained expression in many different cell types (including cell types that typically do not express tubulin III).

[0077] The inventors next sought to determine whether the expression of Cas9 could be "tuned" by partial codon optimization. A Cas9 variant was generated in which the first 606 N-terminal amino acids were codon-optimized using tubulin III preferred codons while the rest of the sequence remained unchanged. This N-terminally codon-optimized Cas9 variant (referred to herein as NOpt-Cas9) is represented by SEQ ID NO: 3:

[0078]

[0079] Similar to CodOpt-Cas9, as iPSC cells develop into more neuronal cell types, NOpt-Cas9 shows improved cutting efficiency relative to old-Cas9. In the later stages of differentiation (e.g., the 10th and 14th days), NOpt-Cas9 shows reduced expression and thus reduced cutting efficiency relative to CodOpt-Cas9, indicating that the degree of codon optimization directly affects the level of protein production as neurons mature. Advantageously, these results show that it is not necessary to codon-optimize the complete Cas9 nucleic acid sequence to achieve increased expression, and Cas9 activity can be adjusted by adjusting the level of codon optimization, and Cas9 fully codon-optimized Cas9 shows higher activity compared to partially codon-optimized variants.

[0080] Result described herein proves, based on the codon bias shown by the endogenous gene of the protein of encoding host cell high expression or based on the codon bias shown by the endogenous gene of the protein of encoding in the cell of the species identical with host cell high expression and the target nucleic acid sequence (for example, target gene) of codon optimization realizes the expression of higher and more continuous level.Advantageously, compared with the sequence that uses the current gold standard method that typically depends on the codon bias of species level to carry out codon optimization, the sequence that carries out codon optimization according to the present invention realizes higher expression.In addition, inventors have shown that the degree that can carry out codon optimization by using method described herein to change sequence to regulate gene expression.

[0081] The present invention provides a method for codon-optimizing a target nucleic acid sequence for expression in a host cell, the method comprising changing the codon usage frequency of the target nucleic acid sequence based on the codon usage frequency of the gene encoding the protein highly expressed in the host cell or the codon usage frequency of the gene encoding the protein highly expressed in the cell from the same species as the host cell. In some embodiments, the present invention provides a method for codon-optimizing a target nucleic acid sequence to improve expression in a host cell. In some embodiments, the present invention provides a method for codon-optimizing a target nucleic acid sequence to increase expression in a host cell. In some embodiments, the gene encoding the protein highly expressed in the host cell is an endogenous gene. In some embodiments, the gene encoding the protein highly expressed in the cell from the same species as the host cell is an endogenous gene.

[0082] As used herein, "codon usage frequency" (also referred to herein as "codon frequency" or "usage frequency") refers to the proportion of each synonymous codon (each codon encodes the same amino acid) present in a sequence or sequence group. A codon usage frequency of 100% indicates that the codon in question is used exclusively for a given amino acid. Methionine (met) and tryptophan (trp) are each encoded by a single codon, so these codons always have a usage frequency of 100%. A codon usage frequency of 0% indicates that the codon is not used by the sequence / sequence group. For a given codon, a codon usage frequency of 25% indicates that the codon in question accounts for 25% of all synonymous codons present in the sequence / sequence group encoding the encoded amino acid (one or more other synonymous codons account for the remaining 75%). In some embodiments, the method includes determining the codon usage frequency of a gene encoding a protein that is highly expressed by a host cell or the codon usage frequency of a gene encoding a protein that is highly expressed by a cell from the same species as the host cell.

[0083] Hereinafter, “a gene encoding a highly expressed protein” refers to a gene encoding a protein that is highly expressed in a host cell or in a cell derived from the same species as the host cell.

[0084] In some embodiments, a non-preferred codon is a codon used by a gene encoding a highly expressed protein at a lower frequency than would be expected if each synonymous codon were used randomly. The random usage frequency depends on the number of synonymous codons available for a given amino acid. For example, for an amino acid encoded by two synonymous codons, each of these synonymous codons will have a random usage frequency of 50%. In this case, a codon usage frequency of less than 50% indicates that the codon is non-preferred. Similarly, for an amino acid encoded by six synonymous codons, each of these synonymous codons will have a random usage frequency of 16.67%, and a codon usage frequency of less than 16.67% indicates that the codon is non-preferred. In some embodiments, a non-preferred codon is a codon used by a gene encoding a highly expressed protein at a lower frequency than one or more other synonymous codons encoding the same amino acid.

[0085] In some embodiments, non-preferred codons are codons used at a frequency of less than 50%, less than 45%, less than 40%, less than 35%, less than 33%, less than 30%, less than 25%, less than 20%, less than 16%, less than 15%, less than 10%, less than 5%, or 0% by genes encoding highly expressed proteins. In some embodiments, genes encoding highly expressed proteins use non-preferred codons at a frequency of less than 10%. In some embodiments, genes encoding highly expressed proteins use non-preferred codons at a frequency of 0%.

[0086] In some embodiments, preferred codons refer to codons used by genes encoding highly expressed proteins at a higher frequency than expected if each synonymous codon is used randomly. As mentioned above, the random usage frequency depends on the number of synonymous codons available for a given amino acid. For example, for an amino acid encoded by two synonymous codons, each of these codons will have a random usage frequency of 50%, so a codon usage frequency of more than 50% indicates a preference for the codon. For an amino acid encoded by six synonymous codons, each of these synonymous codons will have a random usage frequency of 16.67%, so a codon usage frequency of more than 16.67% indicates that the codon is preferred. In some embodiments, preferred codons are codons used by genes encoding highly expressed proteins at a higher frequency than one or more other synonymous codons encoding the same amino acid. In some embodiments, preferred codons are codons used exclusively by genes encoding highly expressed proteins.

[0087] In some embodiments, preferred codons are codons used at a frequency of at least 17%, at least 20%, at least 25%, at least 30%, at least 34%, at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or 100% for genes encoding highly expressed proteins. In some embodiments, genes encoding highly expressed proteins use preferred codons at a frequency of at least 50%. In some embodiments, genes encoding highly expressed proteins use preferred codons at a frequency of at least 75%.

[0088] In some embodiments, at least 50% of the non-preferred codons in the target nucleic acid sequence are replaced with preferred synonymous codons. In some embodiments, the method includes replacing at least 25%, at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or 100% of the non-preferred codons in the target nucleic acid sequence with preferred synonymous codons. In some embodiments, the method includes replacing all non-preferred codons used at a frequency of 0% by genes encoding highly expressed proteins in the target nucleic acid sequence with preferred synonymous codons.

[0089] In some embodiments, the method comprises replacing all non-preferred codons within the target nucleic acid sequence with preferred synonymous codons in a specific region of the target nucleic acid (e.g., the 5' end of the target nucleic acid (encoding the N-terminal region of the protein). In some embodiments, the method comprises replacing all non-preferred codons with preferred synonymous codons in the first at least 100, at least 200, at least 300, at least 400, at least 500, at least 600, at least 700, at least 800, at least 900, at least 1000, at least 1500, or at least 2000 codons starting from the 5' end of the target nucleic acid.

[0090] As used herein, highly expressed proteins are proteins constitutively expressed by host cells or by related cells from the same species as the host cell. Typically, highly expressed proteins can be easily detected using methods known in the art (e.g., Western blot and enzyme-linked immunosorbent assay (ELISA)). Preferably, highly expressed proteins are one of the most highly and / or most stably expressed proteins produced by host cells or related cells. In certain embodiments, highly expressed proteins are among the top 10% most highly expressed proteins in host cells or cells from the same species as the host cell. Skilled technicians can easily identify highly expressed proteins using methods known in the art (e.g., proteomics methods including gel electrophoresis and mass spectrometry). Highly expressed proteins can also be identified using online protein expression databases (e.g., human protein atlas).

[0091] In some embodiments, highly expressed proteins are housekeeping proteins or marker proteins. As used herein, "housekeeping proteins" are constitutively expressed proteins that are necessary for maintaining basic cell functions in host cells or cells from the same species as the host cell, for example, in humans, GAPDH, β-tubulin and β-actin are considered housekeeping genes. In some embodiments, the gene encoding highly expressed proteins is the GAPDH gene. In some embodiments, the gene encoding highly expressed proteins is the β-actin gene. In some embodiments, the gene encoding highly expressed proteins is the β-tubulin gene. As used herein, "cell marker proteins" are proteins that can be used to identify the cell type expressed by a specific cell type, such as tubulin III (also referred to as β-tubulin III, class III β-tubulin or βIII-tubulin) (which is a neuronal cell marker), myosin (which is a muscle cell marker) and alpha-fetoprotein (which is a liver stem cell marker). In some embodiments, the gene encoding highly expressed proteins is the tubulin III gene. In some embodiments, the gene encoding the highly expressed protein is a tubulin III gene transcript, such as a tubulin III transcript represented by SEQ ID NO: 8. In some embodiments, the gene encoding the highly expressed protein is a myosin gene. In some embodiments, the gene encoding the highly expressed protein is an alpha-fetoprotein gene. The highly expressed protein can be a lymphocyte marker protein, such as a T cell marker protein, such as CD4. In some embodiments, the gene encoding the highly expressed protein is a CD4 gene. In some embodiments, non-preferred codons include codons used at a frequency of 0% by genes encoding highly expressed proteins. For example, when the gene encoding a highly expressed protein is a tubulin III gene, non-preferred codons may include: alanine codons GCA, GCG, and GCT; arginine codons AGA and CGT; cysteine ​​codons TGT; glutamine codons CAA; isoleucine codons ATA; leucine codons CTA and TTA; lysine codons AAA; proline codons CCG; serine codons TCC; threonine codons ACA, ACG, and ACT; tyrosine codons TAT; valine codons GTA and GTT; and stop or end codons TAA and TAG. In some embodiments, non-preferred codons include codons used at a lower frequency than would be expected if each synonymous codon were used randomly by a gene encoding a highly expressed protein.For example, when the gene encoding a highly expressed protein is the tubulin III gene, non-preferred codons may also include: asparagine codon AAT; aspartic acid codon GAT; glutamic acid codon GAA; glycine codons GGA, GGG and GGT; histidine codon CAC; isoleucine codon ATT; leucine codons CTC, CTT and TTG; phenylalanine codon TTT; proline codon CCA; serine codons TCA and TCG; and valine codon GTC.

[0092] In some embodiments, preferred codons include codons used at a frequency of 100% by genes encoding highly expressed proteins. For example, when the gene encoding a highly expressed protein is the tubulin III gene, preferred codons may include: alanine codon GCC; cysteine ​​codon TGC; glutamine codon CAG; lysine codon AAG; threonine codon ACC; tyrosine codon TAC; and stop codon TGA. In some embodiments, preferred codons include codons used at a higher frequency by genes encoding highly expressed proteins than one or more other synonymous codons encoding the same amino acid. For example, when the gene is a tubulin III gene, preferred codons may also include: arginine codons AGG, CGA, CGC and CGG; asparagine codon AAC; aspartic acid codon GAC; glutamic acid codon GAG; glycine codon GGC; histidine codon CAT; isoleucine codon ATC; leucine codon CTG; phenylalanine codon TTC; proline codons CCC and CCT; serine codons AGC, AGT and TCT; and valine codon GTG.

[0093] In some embodiments, the host cell is a human cell. In some embodiments, the host cell is an iPSC cell or a differentiated cell derived from an iPSC. In some embodiments, the host cell is an iPSC-derived neuron. In some embodiments, the host cell is a cortical neuron, a dopaminergic neuron, or a motor neuron. In some embodiments, the host cell is an iPSC-derived macrophage. In some embodiments, the host cell is an iPSC-derived cardiomyocyte. In some embodiments, the host cell is an iPSC-derived hepatocyte. In some embodiments, the host cell is a HEK293 cell. For each of these embodiments, in some embodiments, the gene encoding a highly expressed protein is a tubulin III gene.

[0094] In some embodiments, the host cell is a bacterial cell. In some embodiments, the host cell is selected from Escherichia coli, Pseudomonas (e.g., P. aeruginosa, P. putida, P. fluorescens), Lactobacillus (e.g., L. lactis), Streptomyces (e.g., S. coelicolor), Bacillus (e.g., B. subtilis), Acinetobacter, Agrobacterium, Cupriavidus, Clostridium, Rhodobacter, Marinobacter, Klebsiella, Ralstonia, and Rhodococcus.

[0095] In some embodiments, the host cell is a yeast cell. In some embodiments, the host cell is selected from the genus Saccharomyces (e.g., S. cerevisiae), the genus Schizosaccharomyces (e.g., S. pombe), the genus Candida (e.g., C. albicans), the genus Pichia, the genus Hansenula, the genus Klockera, the genus Schwanniomyces, the genus Rhodosporidium, the genus Yarrowia, and the genus Rhodotorula.

[0096] In some embodiments, the host cell is a fungal cell. In some embodiments, the host cell is selected from Aspergillus (e.g., A. niger), Penicillium, Rhizopus, Chrysosporium, Myceliophthora, Trichoderma (e.g., T. reesei), Humicola, Acremonium, and Fusarium.

[0097] In some embodiments, the target nucleic acid is a heterologous nucleic acid. In some embodiments, the target nucleic acid is an endogenous nucleic acid.

[0098] In some embodiments, the target nucleic acid encodes a Cas enzyme. In some embodiments, the target nucleic acid encodes Cas9. In some embodiments, the target nucleic acid encodes Cas12a. In some embodiments, the target nucleic acid encodes Cas13Rx.

[0099] The present invention provides nucleic acid sequences that have been codon-optimized by the methods of the present invention. In some embodiments, the present invention provides codon-optimized nucleic acids encoding Cas9. In some embodiments, the codon-optimized nucleic acids encoding Cas9 comprise at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or 100% sequence identity to SEQ ID NO: 1.

[0100] In some embodiments, the invention provides a nucleic acid encoding Cas9, wherein the 5' region of the nucleic acid is codon optimized by the methods of the invention. In some embodiments, the nucleic acid comprises at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or 100% sequence identity to SEQ ID NO: 3.

[0101] In some embodiments, the invention provides a codon-optimized nucleic acid encoding Cas12a. In some embodiments, the codon-optimized nucleic acid encoding Cas12a comprises at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or 100% sequence identity to SEQ ID NO: 4.

[0102] In some embodiments, the present invention provides a codon-optimized nucleic acid encoding Cas1 3Rx. In some embodiments, the codon-optimized nucleic acid encoding Cas13Rx comprises at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or 100% sequence identity to SEQ ID NO: 5.

[0103] The present invention also provides a vector comprising a nucleic acid that has been codon-optimized by the method of the present invention. In certain embodiments, the vector comprises nucleic acid of the present invention. Suitable vectors will depend on the host cell used, and can be easily identified by a skilled person. In certain embodiments, the vector is selected from adeno-associated virus (AAV) vectors, HIV-based lentiviral vectors, equine immunodeficiency virus (EIV) vectors, feline immunodeficiency virus (FIV) vectors, and herpes simplex virus vectors.

[0104] The vector may comprise one or more of the following: an origin of replication, a promoter sequence operably linked to the nucleic acid of the present invention, and a reporter gene or a selective marker. The promoter may be homologous or heterologous. The promoter may be constitutive or inducible. In certain embodiments, the promoter is inducible and is activated in the presence of an inducer. Inducers include, but are not limited to, sugars, metal salts, and antibiotics. Typically, the promoter is operable in the target host cell.

[0105] In some embodiments, the vector comprises a codon-optimized nucleic acid encoding a Cas enzyme. In some embodiments, the vector comprises a codon-optimized nucleic acid encoding Cas9, Cas12a, or Cas13Rx. In some embodiments, the vector comprises a nucleic acid having at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or 100% sequence identity to any one of SEQ ID NO: 1, 3, 4, or 5.

[0106] The present invention also provides host cells comprising nucleic acid sequences that have been codon-optimized by the methods of the present invention. In some embodiments, the host cells comprise nucleic acids of the present invention. In some embodiments, the host cells comprise vectors of the present invention.

[0107] In some embodiments, the host cell is a human cell. In some embodiments, the host cell is an iPSC cell or a differentiated cell derived from an iPSC. In some embodiments, the host cell is an iPSC-derived neuron. In some embodiments, the host cell is an iPSC-derived macrophage. In some embodiments, the host cell is an iPSC-derived cardiomyocyte. In some embodiments, the host cell is an iPSC-derived hepatocyte. In some embodiments, the host cell is a HEK293 cell.

[0108] In certain embodiments, host cell is bacterial cell.In certain embodiments, host cell is selected from intestinal bacteria, Pseudomonas (for example, Pseudomonas aeruginosa, Pseudomonas putida, Pseudomonas fluorescens), Lactobacillus (for example, Lactococcus lactis), Streptomyces (for example, Streptomyces coelicolor), Bacillus (for example, Bacillus subtilis), Acinetobacter, Agrobacterium, Cupric bacteria, Fusobacterium, Rhodobacter, Marinobacter, Klebsiella, Ralstonia and Rhodococcus.In certain embodiments, host cell is yeast cell.In certain embodiments, host cell is selected from Saccharomyces (for example, Saccharomyces cerevisiae), Schizosaccharomyces (for example, Schizosaccharomyces pombe), Candida (for example, Candida albicans), Pichia, Hansenula, Klerk's yeast, Schwann yeast, red winter spore yeast, Yarrowia and red yeast.In certain embodiments, host cell is fungal cell. In some embodiments, the host cell is selected from Aspergillus (e.g., Aspergillus niger), Penicillium, Rhizopus, Chrysosporium, Myceliophthora, Trichoderma (e.g., Trichoderma reesei), Humicola, Acremonium, and Fusarium.

[0109] In some embodiments, the host cell comprises a codon-optimized nucleic acid encoding a Cas enzyme. In some embodiments, the host cell comprises a codon-optimized nucleic acid encoding Cas9, Cas12a, or Cas13Rx. In some embodiments, the host cell comprises a nucleic acid having at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or 100% sequence identity to any one of SEQ ID NO: 1, 3, 4, or 5.

[0110] The present invention provides iPSCs comprising a nucleic acid sequence encoding Cas9, wherein the nucleic acid sequence has been codon optimized by the method of the present invention. In some embodiments, the iPSCs comprise a nucleic acid having at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or 100% sequence identity to any one of SEQ ID NO: 1.

[0111] The present invention provides iPSC-derived neuronal cells, wherein the neuronal cells comprise a nucleic acid sequence encoding Cas9, wherein the nucleic acid sequence has been codon-optimized by the method of the present invention. In some embodiments, the iPSC-derived neuronal cells comprise a nucleic acid having at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or 100% sequence identity to any one of SEQ ID NO: 1.

[0112] The present invention provides a hepatocyte derived from iPSC, wherein the hepatocyte comprises a nucleic acid sequence encoding Cas9, wherein the nucleic acid sequence has been codon optimized by the method of the present invention. In some embodiments, the hepatocyte derived from iPSC comprises a nucleic acid having at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or 100% sequence identity to any one of SEQ ID NO: 1.

[0113] The present invention provides macrophages derived from iPSCs, wherein the macrophages comprise a nucleic acid sequence encoding Cas9, wherein the nucleic acid sequence has been codon optimized by the method of the present invention. In some embodiments, the macrophages derived from iPSCs comprise a nucleic acid having at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or 100% sequence identity to any one of SEQ ID NO: 1.

[0114] The present invention provides cardiomyocytes derived from iPSCs, wherein the cardiomyocytes comprise a nucleic acid sequence encoding Cas9, wherein the nucleic acid sequence has been codon optimized by the method of the present invention. In some embodiments, the cardiomyocytes derived from iPSCs comprise a nucleic acid having at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or 100% sequence identity to any one of SEQ ID NO: 1.

[0115] The present invention provides iPSCs comprising a nucleic acid sequence encoding Cas9, wherein the nucleic acid sequence has been codon optimized by the method of the present invention. In some embodiments, the iPSCs comprise a nucleic acid having at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or 100% sequence identity to any one of SEQ ID NO: 3.

[0116] The present invention provides iPSC-derived neuronal cells, wherein the neuronal cells comprise a nucleic acid sequence encoding Cas9, wherein the nucleic acid sequence has been codon-optimized by the method of the present invention. In some embodiments, the iPSC-derived neuronal cells comprise a nucleic acid having at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or 100% sequence identity to any one of SEQ ID NO: 3.

[0117] The present invention provides a hepatocyte derived from iPSC, wherein the hepatocyte comprises a nucleic acid sequence encoding Cas9, wherein the nucleic acid sequence has been codon optimized by the method of the present invention. In some embodiments, the hepatocyte derived from iPSC comprises a nucleic acid having at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or 100% sequence identity to any one of SEQ ID NO: 3.

[0118] The present invention provides iPSC-derived macrophages, wherein the macrophages comprise a nucleic acid sequence encoding Cas9, wherein the nucleic acid sequence has been codon-optimized by the method of the present invention. In some embodiments, the iPSC-derived macrophages comprise a nucleic acid having at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or 100% sequence identity to any one of SEQ ID NO: 3.

[0119] The present invention provides cardiomyocytes derived from iPSCs, wherein the cardiomyocytes comprise a nucleic acid sequence encoding Cas9, wherein the nucleic acid sequence has been codon optimized by the method of the present invention. In some embodiments, the cardiomyocytes derived from iPSCs comprise a nucleic acid having at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or 100% sequence identity to any one of SEQ ID NO: 3.

[0120] The present invention provides iPSCs comprising a nucleic acid sequence encoding Cas 12a, wherein the nucleic acid sequence has been codon optimized by the method of the present invention. In some embodiments, the iPSC comprises a nucleic acid having at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or 100% sequence identity to any one of SEQ ID NO: 4.

[0121] The present invention provides iPSC-derived neuronal cells, wherein the neuronal cells comprise a nucleic acid sequence encoding Cas12a, wherein the nucleic acid sequence has been codon-optimized by the method of the present invention. In some embodiments, the iPSC-derived neuronal cells comprise a nucleic acid having at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or 100% sequence identity to any one of SEQ ID NO: 4.

[0122] The present invention provides iPSC-derived hepatocytes, wherein the hepatocytes comprise a nucleic acid sequence encoding Cas12a, wherein the nucleic acid sequence has been codon-optimized by the method of the present invention. In some embodiments, the iPSC-derived hepatocytes comprise a nucleic acid having at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or 100% sequence identity to any one of SEQ ID NO: 4.

[0123] The present invention provides iPSC-derived macrophages, wherein the macrophages comprise a nucleic acid sequence encoding Cas12a, wherein the nucleic acid sequence has been codon-optimized by the method of the present invention. In some embodiments, the iPSC-derived macrophages comprise a nucleic acid having at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or 100% sequence identity to any one of SEQ ID NO: 4.

[0124] The present invention provides cardiomyocytes derived from iPSC, wherein the cardiomyocytes comprise a nucleic acid sequence encoding Cas12a, wherein the nucleic acid sequence has been codon optimized by the method of the present invention. In some embodiments, the cardiomyocytes derived from iPSC comprise a nucleic acid having at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or 100% sequence identity to any one of SEQ ID NO: 4.

[0125] The present invention provides iPSCs comprising a nucleic acid sequence encoding Cas13Rx, wherein the nucleic acid sequence has been codon optimized by the method of the present invention. In some embodiments, the iPSC comprises a nucleic acid having at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or 100% sequence identity to any one of SEQ ID NO: 5.

[0126] The present invention provides iPSC-derived neuronal cells, wherein the neuronal cells comprise a nucleic acid sequence encoding Cas1 3Rx, wherein the nucleic acid sequence has been codon-optimized by the method of the present invention. In some embodiments, the iPSC-derived neuronal cells comprise a nucleic acid having at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or 100% sequence identity to any one of SEQ ID NO: 5.

[0127] The present invention provides iPSC-derived hepatocytes, wherein the hepatocytes comprise a nucleic acid sequence encoding Cas13Rx, wherein the nucleic acid sequence has been codon-optimized by the method of the present invention. In some embodiments, the iPSC-derived hepatocytes comprise a nucleic acid having at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or 100% sequence identity to any one of SEQ ID NO: 5.

[0128] The present invention provides iPSC-derived macrophages, wherein the macrophages comprise a nucleic acid sequence encoding Cas1 3Rx, wherein the nucleic acid sequence has been codon-optimized by the method of the present invention. In some embodiments, the iPSC-derived macrophages comprise a nucleic acid having at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or 100% sequence identity to any one of SEQ ID NO: 5.

[0129] The present invention provides cardiomyocytes derived from iPSC, wherein the cardiomyocytes comprise a nucleic acid sequence encoding Cas1 3Rx, wherein the nucleic acid sequence has been codon optimized by the method of the present invention. In some embodiments, the cardiomyocytes derived from iPSC comprise a nucleic acid having at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or 100% sequence identity to any one of SEQ ID NO: 5.

[0130] Examples

[0131] The present invention will be further illustrated by the following non-limiting examples.

[0132] Example 1

[0133] Cas9 silencing in differentiated cells

[0134] A variety of approaches have been used to try to overcome Cas9 silencing during iPSC differentiation. Such approaches include using lentiviruses / transposons to integrate multiple copies of Cas9 into the host cell genome; testing Cas9 expression under different mammalian expression promoters; and targeting Cas9 to genomic safe harbor sites. Despite these efforts, researchers have observed that Cas9 protein levels in differentiated cells are significantly reduced compared to levels observed in iPSCs. Interestingly, despite the reduction in protein levels, Cas9 mRNA levels remain detectable during differentiation.

[0135] The inventors first confirmed that Cas9 expression decreases during iPSC differentiation ( Figure 1 ). Use PiggyBac transposase to generate stable Cas9-expressing iPSCs (Plasmid schematic, Figure 1A) and then differentiated into dopaminergic neurons. RNA collected at days 10 and 20 was analyzed for Cas9 expression and GAPDH expression during differentiation. By day 20, Cas9 mRNA decreased by approximately 60% ( Figure 1 B).

[0136] In an attempt to circumvent Cas9 silencing, the inventors generated the Bob-iNgn2GAPDH-Cas9 iPSC line. Cas9 was inserted into the site of the housekeeping gene GAPDH to ensure continuous transcription. GAPDH was selected as a good housekeeping gene for knocking in Cas9 because GAPDH levels were shown to gradually increase during the iPSC-derived neuronal differentiation protocol ( Figure 1 C). Knock-in Cas9 just upstream of GAPDH using homology-directed recombination ( Figure 2 A).

[0137] Cas9 and GAPDH mRNA and protein levels were assessed during cortical neuron differentiation, which was rapid (14 days) and driven using the inducible Ngn2 transgene. Results from RT-qPCR at the mRNA level demonstrated that expression of Cas9 was comparable to that of GAPDH during iPSC differentiation into neurons ( Figure 2 B), which is encouraging compared to results obtained from Cas9 using random integration of transposons as previously observed.

[0138] Cas9 protein levels were determined using Western blotting ( Figure 3 A and Figure 3 B), and Cas9 nuclease activity was determined using a fluorescent reporter construct ( Figure 3 C- Figure 3 E). Despite encouraging evidence at the mRNA level, after 4 days in differentiation medium, the cell line showed a loss of Cas9 protein and therefore Cas9 activity. Thus, despite a successful knock-in at the endogenous GAPDH gene, the promoter of the housekeeping gene was unable to maintain constitutive expression of Cas9 protein during iPSC differentiation into neuronal cell types.

[0139] To determine whether Cas9 silencing at the protein level in differentiated neurons was a result of protein degradation via the proteasome or autophagy pathway, the inventors blocked proteasome degradation using the MG132 inhibitor and the autophagy-lysosome pathway using bafilomycin A1 (BafA1). Experiments on day 7 neurons, where Cas9 levels showed a 60% decrease compared to day 4, showed that blocking these protein degradation pathways did not rescue Cas9 levels ( Figure 4 A).

[0140] Given that Cas9 levels appear to drop dramatically between days 4 and 7 of cortical neuron differentiation, consistent with changes in differentiation medium according to the cortical neuron generation protocol, the inventors additionally tested alternative protocols during differentiation to determine whether Cas9 levels drop in the presence of culture medium or can be rescued by retaining the supplements used from day 0 to day 4 of the protocol. These experiments demonstrated that Cas9 silencing could not be rescued by changing the culture medium composition ( Figure 4 B).

[0141] Cas9 codon optimization

[0142] The presence of Cas9 mRNA and the lack of Cas9 protein indicate that Cas9 transcription is uncoupled from Cas9 translation. Since Cas9 silencing is particularly evident during the 4th to 7th day of neuronal differentiation, the inventors believe that the neuronal phenotype of the cell hinders Cas9 expression. A large amount of evidence shows that synonymous codon selection in natural mRNA has evolved in response to different selection pressures at both RNA and protein levels. Therefore, the inventors hypothesize that Cas9 may require further codon optimization to function in differentiated cell types.

[0143] Comparison of universal codon usage frequencies between E. coli and humans (obtained from Kazusa's codon usage database (Nakamura, Y. et al. Nucleic acids research 2000 28(1): 292) - available at https: / / www.kazusa.or.jp / codon / ) Figure 5 ). The comparison shows that the codon usage between the two organisms is quite comparable. However, the amino acids (such as Asp, Arg, His, Val, etc.) that have been highlighted using dashed boxes show significant differences in usage in humans compared to bacteria. These small differences lead to substantial changes in protein translation, and the effect is compounded in large proteins (such as Cas9, which has over 1000 codons).

[0144] Based on the existing gold standard method based on human codon usage frequency, the existing Cas9 (o1d-Cas9) sequence (SEQ ID NO: 2) was optimized for expression in human cells ( Figure 6 ).

[0145] The inventors sought to determine whether differentiated neurons, which are post-mitotic in nature, exhibit a codon bias that differs from the universal human codon bias by determining the codon usage frequency of the highly expressed neuronal marker tubulin III (Tuj 1). The inventors analyzed the codon distribution of an identified protein-coding transcript for tubulin III (Ensembl transcript: TUBB3-208ENST00000555576.5; SEQ ID NO: 8) using the Codon Calculator tool available at https: / / www.biologicscorp.com / tools / CodonUsageCalculator / . The codon usage frequency of tubulin III was compared to the universal human codon usage ( Figure 7 ).

[0146] Codon usage frequency of tubulin III shows that the codon preference of tubulin III is different from the universal codon usage of humans. Key differences are highlighted by dashed boxes (unused) and triangles (highly used) ( Figure 7 ).

[0147] Using the codon usage frequency of tubulin III, a novel codon-optimized Cas9 variant (CodOpt-Cas9) with altered codons was generated. The DNA sequence of the codon-optimized Cas9 is provided below, with the codons that have been altered highlighted in bold:

[0148]

[0149]

[0150]

[0151]

[0152]

[0153] To ensure that only the codons of Cas9 were changed and not the amino acid (protein) sequence, the inventors verified the protein sequences produced by the two variants of Cas9 using the ClustalW protein alignment tool.

[0154] The codon usage frequency of CodOpt-Cas9 was compared with the universal codon usage of humans ( Figure 8 ). This comparison demonstrates that codon optimization of Cas9 using the codon bias of tubulin III produces a sequence with a codon usage frequency that is substantially different from the universal codon usage in humans.

[0155] CodIpt-Cas9 expression and activity

[0156] The inventors cloned the codon-optimized Cas9 into an expression construct directly comparable to the o1d-Cas9 expression construct ( Fig. 9 Initially, the inventors tested and compared old-Cas9 and CodOpt-Cas9 expression in HEK293 cells. Advantageously, these experiments demonstrated that CodOpt-Cas9 had increased expression at both the mRNA and protein levels compared to old-Cas9 ( Fig.10 ).

[0157] Cas9 activity assays using fluorescent reporter plasmids were performed using HEK293 cells with each of these two variants of Cas9. The results of these Cas9 cleavage assays demonstrated that CodOpt-Cas9 exhibited higher nuclease activity and initiated editing much faster than old-Cas9 ( Fig.10 D). This faster cleavage efficiency can also be observed through the formation of indels when Cas9 is directed to edit a non-essential gene in the genome (ST6GALNAC6) ( Fig.11 ). These results indicate that CodOpt-Cas9 achieves higher expression than old-Cas9 and exhibits faster and more efficient cleavage.

[0158] Next, the inventors attempted to express CodOpt-Cas9 in Bob-iNgn2 iPSCs. CodOpt-Cas9 lines were generated using PiggyBac transposase. Cas9 expression was examined at both mRNA and protein levels. Similar to HEK293 cells, iPSCs with CodOpt-Cas9 exhibited high levels of Cas9 mRNA and protein ( Fig.12 ).

[0159] Bob-iNgn2 iPSCs containing CodOpt-Cas9 or old-Cas9 were then differentiated into cortical neurons. Western blotting of the protein level of Cas9 showed that Cas9 could be readily detected in differentiated neuronal cells expressing CodOpt-Cas9 ( Fig.13 However, as observed in previous experiments, cells expressing old-Cas9 showed a dramatic decrease in Cas9 levels as the cells entered a more neuronal phenotype ( Fig.13 ).

[0160] These results indicate that optimizing the codon usage of Cas9 to reflect the codon usage of the highly expressed neuronal marker protein tubulin III significantly improved Cas9 expression in iPSCs and iPSC-derived neurons. Advantageously, Cas9 expression persisted throughout differentiation into neurons, significantly improving the potential research applications of both iPSC-derived cell lines and the CRISPR-Cas9 system ( Fig.13 ).

[0161] Codon optimization as a tool to control expression levels

[0162] Recently, codon usage has come into focus as a key determinant of translation elongation rate and co-translational protein folding, with preferred codons improving translation efficiency and folding fidelity. From yeast to humans, the unequal use of synonymous codons (known as codon bias) and the universal nature of this bias suggest the existence of a secondary code within the more familiar genetic code. This secondary code emerges as a major regulator of translation rate and co-translational protein folding and therefore as an important determinant of the cellular level of a particular protein.

[0163] Based on the observation that CodOpt-Cas9 achieved better expression at both mRNA and protein levels in HEK293 cells and iPSCs compared to old-Cas9, the inventors tested whether the level of Cas9 could be adjusted by partial codon optimization. A Cas9 variant was generated in which the first 606 amino acid codons were optimized based on tubulin III codon usage, while the remaining codons were unchanged. This form of Cas9 (which encodes a protein with codon optimization for the N-terminal region) is represented by SEQ ID NO: 3 and is referred to herein as NOpt-Cas9.

[0164] Bob iPSC cell line containing old-Cas9, CodOpt-Cas9 and NOpt-Cas9 was generated using PiggyBac integration ( Fig.14 ) and then differentiated into neurons. Cas9 cleavage efficiency was determined at the iPSC stage and throughout various stages of neuronal differentiation.

[0165] It was found that as cells progress toward neuronal fate, NOpt-Cas9 and CodOpt-Cas9 have better cutting efficiency than Old Cas9 ( Fig.15 Interestingly, experiments performed in more differentiated cells (day 10 and day 14 neurons) demonstrated a slight decrease in cutting efficiency for NOpt-Cas9 compared to CodOpt-Cas9. Despite this decrease in editing efficiency, NOpt-Cas9 did exhibit higher cutting compared to old-Cas9 at these time points ( Fig.15 and Fig.16 ). Cleavage efficiency was assessed 4 and 7 days after cell transduction.

[0166] The inventors also evaluated Cas9 expression at the mRNA and protein levels to determine how partial optimization affects transcription and translation. Both complete and partial codon optimization of Cas9 resulted in increased mRNA levels and sustained expression during differentiation ( Fig.17 A). Interestingly, it was noted that in the cell line containing NOpt-Cas9, Cas9 levels in neurons were significantly reduced after day 7 ( Fig.17 B and Fig.17 C; box highlights for comparison). While this reflects a reduction in NOpt-Cas9 editing efficiency, it suggests that the altered codons contribute to sustained protein expression as neurons mature in vitro.

[0167] Cas9 expression in non-neuronal iPSC-derived cell types

[0168] Similar to iPSC-derived neurons, robust and sustained expression of Cas9 has not been previously achieved in other iPSC-derived cell types, such as hepatocytes and macrophages. Therefore, the inability to perform CRISPR-Cas9 whole genome screening limits the use of these cell lines to their progenitor state, similar to the limitations observed when performing Cas9 screening in differentiated neurons. Therefore, the inventors set out to determine whether Cas9 expression could be achieved when differentiating CodOpt-Cas9 iPSC lines into other cell types.

[0169] Hepatocytes were obtained from iPSCs based on a protocol established by (Hannan et al. Nature protocols. 8, 430-437 (2013)). Similar to differentiated neurons, Cas9 levels have been observed to drop dramatically after day 7 of differentiation as cells undergo multiple morphological changes before becoming epithelial lineages.

[0170] Bob iPSC cells with old-Cas9 or CodOpt-Cas9 were differentiated into hepatocytes, and cell pellets were collected on days 0, 4, and 10 of differentiation. Western blotting revealed that CodOpt-Cas9 levels were significantly higher than old-Cas9 levels in iPSC-derived hepatocyte-like cells, especially after day 7 ( Fig.18 ).

[0171] These results demonstrate that CodOpt-Cas9 is able to reach and maintain high expression levels in iPSC-derived cells other than neurons. Advantageously, these results demonstrate that a variety of cell types, including cells that do not normally express genes encoding highly expressed proteins upon which codon optimization is based, can have significant improvements in target nucleic acid expression.

[0172] Summarize

[0173] These results show that codon optimization of target nucleic acids using codon biases of genes encoding highly expressed proteins significantly improves the expression of the nucleic acid in a range of cell types (even cell types that do not express highly expressed genes). In addition, partial codon optimization can be performed on the target nucleic acid to regulate expression levels. Therefore, the methods described herein can be used as a solution to overcome Cas9 silencing and allow CRISPR-Cas9 whole genome screening in various cell lines (including differentiated cell types).

[0174] Example 2

[0175] Codon optimization of Cas12a and Cas13Rx

[0176] In addition to Cas9, Cas12a and Cas 13Rx have become promising tools for gene editing. These CRISPR Cas proteins have been used to edit DNA and RNA, respectively, greatly increasing the potential of gene editing technology. The inventors analyzed existing variants of Cas12a and Cas13Rx to determine whether they have been fully codon-optimized for human mammalian cells.

[0177] Codon-optimized Cas12a

[0178] The codon usage of the current variants of Cas12a is based on existing gold standards, and the optimization pattern is similar to that observed in old-Cas9 ( Fig.19 ). The starting Cas12a sequence was obtained from the following addgene plasmid IDs: 160573 and 78744, and is represented by SEQ ID NO: 6:

[0179]

[0180] As described above, the inventors codon-optimized the Cas12a sequence to match the codon usage of tubulin III ( Figure 7 ). The codon-optimized Cas12a (CodOpt-Cas12a) DNA sequence is represented by SEQ ID NO: 4, in which the changed codons are highlighted in bold:

[0181] TAC ATC AGC CTG TTT CGG AAG AAG ACC CGG ACC GAGAAG GAG AAT AAG GAG CTT GAGAAC CTG GAG ATC AACCTC CGG AAG GAG ATC GCC AAG GCC TTC AAG GGC AAC GAGGGC TACAAG TCC CTG TTC AAG AAG GAC ATC ATA GAG ACCATC CTG CCC GAG TTC CTT GAC GACAAG GAC GAG ATC GCCCTG GTG AAC AGC TTC AAC GGC TTC ACC ACC GCC TTC ACCGGC TTCTTC GAC AAC CGG GAG AAC ATG TTT AGC GAG GAGGCC AAG TCT ACC AGC ATC GCC TTCAGG TGC ATC AAC GAGAAC CTT ACT CGG TAC ATC AGC AAC ATG GAC ATC TTC GAGAAG GTGGAC GCG ATC TTC GAC AAG CAT GAG GTG CAGGAG ATC AAG GAG AAG ATC CTC AAC AGCGAC TAC GACGTC GAG GAC TTC TTC GAG GGG GAG TTC TTC AAC TTC GTGCTT ACC CAG GAAGGC ATC GAC GTG TAC AAC GCC ATC ATCGGC GGC TTC GTG ACC GAG TCT GGC GAG AAGATC AAGGGC CTG AAC GAG TAC ATC AAT CTC TAC AAT CAG AAG ACCAAA CAG AAG CTT CCCAAG TTC AAA CCC CTG TAC AAG CAGGTG CTG TCT GAC CGG GAG TCT CTT AGC TTC TACGGC GAGGGA TAC ACC TCT GAC GAG GAG GTG CTG GAG GTA TTC CGGAAC ACC CTG AAT AAGAAC AGT GAG ATC TTC AGC TCT ATCAAG AAA CTG GAG AAG CTT TTC AAG AAT TTT GACGAG TACAGC AGT GCTGGC ATC TTC GTG AAA AAC GGC CCA GCC ATCAGT ACC ATC TCT AAGGAC ATC TTC GGC GAG TGG AAC GTGATC AGG GAC AAG TGG AAC GCC GAG TAC GAC GACATC CACCTT AAG AAG AAG GCA GTC GTG ACC GAG AAG TAC GAG GACGAC AGA CGG AAG TCTTTC AAG AAG ATC GGA AGC TTC AGCTTG GAG CAG CTC CAA GAG TAC GCA GAC GCT GACCTG TCCGTG GTG GAG AAG CTG AAG GAG ATT ATT ATC CAG AAG GTGGAC GAG ATT TAC AAGGTG TAC GGC TCT AGC GAG AAG CTTTTC GAC GCC GAC TTC GTG CTG GAG AAA TCT CTGAAG AAAAAC GAC GCC GTG GTG GCC ATT ATG AAG GAC CTG CTG GACTCT GTG AAG AGC TTCGAG AAC TAC ATC AAG GCC TTC TTCGGC GAA GGA AAG GAG ACC AAC AGA GAC GAG AGCTTC TACGGC GAC TTC GTG CTG GCC TAC GAC ATC CTG CTG AAG GTGGAC CAC ATT TAC GACGCC ATT AGA AAC TAC GTG ACC CAGAAG CCT TAC AGC AAG GAC AAA TTC AAG CTT TACTTC CAGAAC CCC CAG TTC ATG GGG GGC TGG GAC AAG GAC AAG GAGACC GAC TAC AGA GCCACC ATC CTT AGA TAC GGA TCT AAGTAC TAC CTT GCC ATC ATG GAC AAG AAG TAC GCCAAG TGCCTG CAG AAG ATT GAC AAG GAC GAC GTG AAC GGA AAC TACGAG AAG ATT AAC TACAAG CTG CTG CCC GGC CCT AAC AAGATGCTT CCC AAG GTG TTC TTC AGC AAG AAG TGGATG GCCTAC TAC AAC CCT AGT GAG GAC ATT CAG AAG ATC TAC AAGAAT GGC ACC TTC AAGAAG GGC GAC ATG TTC AAC CTT AACGAC TGC CAC AAG CTG ATC GAC TTC TTT AAG GACAGC ATCAGT AGA TAC CCC AAG TGG TCC AAC GCC TAC GAC TTC AACTTC TCT GAG ACA GAGAAG TAT AAG GAC ATT GCT GGT TTTTAC AGG GAG GTG GAG GAG CAG GGC TAC AAG GTGAGCTTC GAG TCT GCC AGC AAG AAG GAG GTG GAC AAA CTGGTG GAG GAG GGC AAG CTG TACATG TTT CAA ATT TAC AATAAG GAC TTC AGC GAC AAG AGC CAC GGC ACT CCT AAT CTGCACACC ATG TAC TTC AAA CTG CTT TTC GAC GAG AAC AATCAT GGC CAG ATC AGA CTG TCCGGC GGC GCC GAG TTG TTCATG AGA AGA GCC AGC CTG AAG AAG GAG GAG CTG GTGGTG CACCCC GCC AAT TCT CCC ATC GCT AAC AAG AAC CCCGAC AAC CCC AAG AAG ACT ACC ACCCTT AGC TAC GAC GTATAC AAG GAC AAG CGG TTT AGC GAG GAC CAG TAC GAGCTG CAC ATCCCC ATC GCC ATC AAC AAG TGC CCG AAG AATATT TTC AAG ATC AAC ACT GAG GTG AGAGTC CTG CTG AAGCAC GAC GAC AAC CCC TAC GTG ATC GGC ATC GAC AGA GGCGAG AGA AACCTC CTG TAC ATC GTG GTG GTG GAC GGC AAGGGC AAT ATCGTG GAG CAG TAC AGC CTTAAC GAG ATT ATCAAC AAC TTC AAC GGC ATC AGA ATT AAG ACC GAC TAC CACTCC CTG CTGGAC AAG AAG GAA AAG GAG AGA TTC GAG GCCAGG CAG AAC TGG ACA AGC ATT GAG AACATC AAG GAGCTG AAG GCC GGC TAC ATC AGC CAA GTT GTG CAC AAG ATTTGC GAG CTG GTGGAG AAA TAC GAC GCC GTG ATC GCC TTGGAG GAC CTC AAC AGC GGC TTC AAG AAC TCTCGG GTG AAGGTG GAG AAG CAG GTG TAC CAG AAG TTC GAG AAG ATG CTGATT GAC AAG CTGAAC TAT ATG GTG GAC AAG AAG AGC AACCCC TGC GCC ACA GGC GGC GCT CTG AAG GGCTAC CAA ATCACC AAC AAG TTC GAG AGC TTC AAG TCA ATG TCT ACC CAGAAC GGC TTC ATCTTC TAC ATC CCT GCC TGG CTT ACC TCCAAG ATC GAT CCG AGC ACC GGC TTT GTG AATTTG CTT AAGACT AAG TAC ACT TCT ATC GCC GAC TCC AAA AAG TTC ATTAGC TCT TTC GACAGA ATC ATG TAT GTG CCC GAA GAG GACCTG TTC GAA TTT GCC CTC GAC TAC AAG AATTTC TCC AGGACT GAC GCT GAC TAT ATC AAG AAG TGG AAG CTG TAC AGCTAT GGC AAC AGAATC CGA ATC TTC CGC AAC CCA AAG AAGAAC AAT GTC TTC GAT TGG GAG GAG GTG TGCTTG ACT AGCGCC TAC AAG GAG CTG TTC AAC AAG TAT GGC ATT AAC TATCAG CAAGGC GACATC CGG GCA CTG CTG TGT GAG CAA TCTGAC AAA GCC TTT TAC AGC TCT TTT ATG GCTCTT ATG TCTCTC ATG TTG CAG ATG AGA AAC AGC ATC ACC GGC AGA ACTGAC GTG GAC TTCCTC ATT TCT CCC GTG AAG AAC TCC GACGGC ATC TTC TAC GAC TCT AGA AAC TAC GAAGCC CAG GAGAAC GCC ATC CTG CCC AAA AAC GCC GAC GCC AAC GGCGCC TAC AAC ATC GCCAGA AAG GTG CTG TGG GCC ATC GGGCAG TTC AAG AAA GCC GAG GAC GAG AAG CTT GACAAA GTGAAG ATC GCC ATC AGC AAC AAG GAG TGG CTG GAG TAC GCCCAG ACC AGC GTG AAGCAC TGA(SEQ ID NO: 4)

[0182] Codon usage frequency of CodOpt-Cas 12a ( Fig. 20 ) and the codon usage frequency of tubulin III ( Figure 7 )similar.

[0183] Codon-optimized Cas13Rx

[0184] A similar approach was taken for Cas13Rx. The codon usage of the current variants of Cas13Rx was based on existing gold standards, and the optimization pattern was similar to that observed in old-Cas9 ( Fig.21 ). The starting Cas1 3Rx sequence was obtained from the following addgene plasmid ID: 141320, and is represented by SEQ ID NO: 7:

[0185]

[0186] Codon bias for tubulin III ( Figure 7 ) The Cas1 3Rx sequence was codon optimized. The DNA sequence of the codon-optimized Cas13Rx (CodOpt-Cas13Rx) is represented by SEQ ID NO: 5, in which the changed codons are highlighted in bold:

[0187] ATG AGC GAG GCC AGC ATC GAG AAG AAG AAA TCT TTCGCC AAG GGC ATG GGCGTG AAG AGC ACC CTG GTG TCTGGC AGC AAG GTG TAC ATG ACC ACC TTC GCC GAG GGCTCTGAC GCC CGG CTG GAG AAG ATA GTT GAG GGC GAC AGCATC CGG AGC GTG AAC GAG GGCGAG GCC TTC TCA GCCGAG ATG GCC GAC AAG AAC GCC GGC TAC AAG ATT GGG AACGCG AAGTTT AGT CAT CCC AAG GGC TAC GCC GTG GTG GCCAAC AAC CCC CTG TAC ACC GGC CCCGTG CAG CAG GAC ATGCTG GGC CTG AAG GAG ACC CTG GAG AAG AGG TAC TTCGGC GAG TCTGCC GAC GGC AAC GAC AAC ATC TGC ATCCAG GTG ATC CAC AAC ATC CTG GAC ATC GAGAAG ATC CTGGCC GAG TAC ATC ACC AAC GCC GCC TAC GCC GTG AAC AACATC AGC GGC CTGGAC AAG GAC ATT ATC GGC TTT GGCAAG TTT TCT ACC GTG TAC ACC TAC GAC GAG TTCAAA GACCCT GAA CAT CAT CGG GCC GCC TTC AAC AAC AAC GAT AAGCTG ATT AAC GCC ATCAAG GCC CAG TAC GAC GAG TTC GACAAC TTC CTG GAC AAC CCA CGA CTG GGC TAC TTTGGC CAGGCT TTC TTC AGC AAG GAG GGA AGA AAC TAC ATC ATC AACTAC GGA AAC GAG TGCTAT GAC ATT CTC GCC CTC CTG TCTGGC CTG AGA CAC TGG GTC GTA CAC AAC AAC GAGGAG GAGTCT CGG ATT AGC AGAACC TGG CTG TAC AAC CTG GAT AAAAAC CTC GAC AAC GAGTAC ATC TCT ACC CTT AAC TAC CTGTAC GAC AGA ATC ACC AAC GAG CTC ACC AAT TCTTTC TCTAAG AAC TCT GCC GCC AAC GTG AAC TAC ATT GCC GAG ACCCTG GGG ATT AAC CCCGCC GAG TTC GCC GAG CAG TAC TTCAGA TTC AGC ATT ATG AAG GAG CAG AAG AAC CTGGGC TTTAAC ATC ACC AAG CTG AGA GAG GTG ATG CTG GAC AGGAAG GAC ATG AGC GAG ATCCGA AAG AAC CAT AAG GTG TTCGAC AGC ATC AGG ACC AAG GTG TAC ACC ATG ATG GACTTCGTC ATC TAC AGG TAC TAC ATC GAG GAG GAC GCC AAG GTGGCT GCG GCA AAC AAG AGCCTG CCT GAT AAC GAG AAG AGCCTG TCT GAG AAG GAC ATC TTC GTG ATC AAT CTG AGAGGTTCT TTC AAC GAC GAC CAA AAG GAC GCC CTG TAC TAT GACGAA GCC AAC AGG ATT TGGCGA AAG CTG GAG AAC ATC ATGCAC AAC ATC AAG GAG TTC AGG GGC AAT AAG ACA CGCGAGTAC AAG AAG AAG GAC GCC CCC AGA CTG CCC AGA ATTCTG CCC GCC GGC AGG GAT GTGAGC GCC TTC TCT AAG CTGATG TAT GCC CTG ACC ATG TTT CTG GAC GGC AAA GAG ATCAACGAC CTG TTG ACC ACC TTG ATC AAC AAA TTT GAC AACATC CAG AGC TTC CTG AAG GTGATG CCC TTG ATC GGC GTGAAC GCC AAG TTC GTGGAG GAG TAC GCC TTC TTC AAA GACTCTGCC AAG ATT GCC GAC GAA CTG AGA CTG ATC AAG TCTTTC GCC AGG ATG GGA GAG CCCATC GCC GAT GCC AGG AGGGCC ATG TAC ATC GAT GCC ATC CGG ATC CTG GGC ACC AACCTGTCT TAC GAC GAG CTG AAA GCC CTG GCC GAC ACC TTTTCC CTG GAC GAG AAC GGC AACAAG CTT AAG AAG GGC AAGCAC GGC ATG AGA AAC TTC ATC ATC AAC AAC GTG ATC AGCAACAAG AGG TTC CAT TAC CTG ATC AGG TAC GGC GAC CCCGCC CAT CTG CAC GAG ATT GCCAAG AAC GAA GCC GTG GTGAAG TTC GTG CTG GGC CGG ATT GCT GAC ATC CAG AAG AAGCAAGGC CAG AAC GGC AAG AAC CAG ATC GAC AGG TAC TACGAA ACC TGT ATT GGC AAG GACAAG GGC AAG AGC GTG TCTGAG AAG GTG GAC GCC CTC ACC AAG ATC ATT ACC GGC ATGAACTAC GAC CAG TTC GAC AAG AAG AGG TCT GTG ATT GAAGAC ACC GGA CGG GAG AAC GCCGAG AGA GAA AAG TTCAAG AAG ATT ATC AGC TTG TAC CTG ACC GTG ATT TAC CATATC CTGAAG AAC ATC GTG AAC ATC AAC GCC CGG TAC GTGATC GGC TTC CAC TGC GTG GAG CGGGAC GCC CAG CTGTAC AAG GAG AAG GGC TAC GAT ATC AAT CTG AAA AAG CTGGAG GAG AAGGGC TTC TCC AGC GTG ACC AAG CTG TGCGCC GGC ATC GAC GAG ACCGCC CCC GAC AAGCGG AAA GACGTG GAG AAG GAG ATG GCC GAG AGG GCC AAG GAG TCT ATCGAC TCT CTG GAGTCT GCC AAC CCC AAG CTT TAT GCG AATTAC ATC AAG TAC AGC GAC GAG AAA AAG GCCGAG GAG TTTACC AGG CAG ATC AAT CGG GAG AAG GCC AAA ACC GCCCTG AAC GCC TAC CTGCGC AAC ACC AAG TGG AAC GTG ATTATC CGG GAG GAC CTG CTG CGG ATT GAC AAC AAGACC TGCACC TTG TTC AGG AAC AAG GCC GTG CAT CTG GAG GTG GCCAGG TAC GTG CAC GCCTAC ATT AAC GAC ATC GCC GAG GTGAAT TCC TAC TTT CAG CTG TAC CAC TAC ATA ATGCAA AGAATC ATC ATG AAC GAA AGG TAC GAG AAG AGC AGC GGC AAGGTG AGC GAG TAC TTCGAC GCC GTG AAC GAC GAG AAG AAATAC AAC GAT CGG CTC CTG AAG CTG CTG TGT GTGCCC TTTGGC TAC TGC ATC CCT AGA TTC AAG AAC CTT TCT ATC GAGGCC CTG TTC GAC CGGAAC GAG GCC GCC AAG TTT GAT AAGGAG AAA AAG AAG GTG AGC GGC AAC AGC GGC AGCGGCTGA(SEQ ID NO:5)

[0188] Codon usage frequency of CodOpt-Cas 13Rx ( Fig. 22 ) is similar to that of tubulin III ( Figure 7 ).

[0189] Based on the promising results presented herein for Cas9, the inventors hypothesized that other codon-optimized genes, such as codon-optimized variants of Cas12a and Cas13Rx described herein, would be beneficial for genome editing in various iPSC-derived cell types (e.g., neurons and hepatocytes).

[0190] Example 3

[0191] Codon Optimization of L-Lactate Dehydrogenase

[0192] The inventors next sought to confirm that the novel codon optimization technique could be applied to other bacterial genes. Using the existing gold standard method based on human codon usage frequency ( Fig.23 and Fig.24 ) and using the codon bias of tubulin III as described herein (in Fig.23 and Fig.24 The Lldr from E. coli (which constitutes the L-lactate dehydrogenase operon element) was codon optimized (denoted as "novel optimization" in the Figure 1) and used to construct two plasmids. Both plasmids also have an eGFP fluorescent reporter to enable evaluation of transfection efficiency.

[0193] HEK293 cells and iPSCs were transfected with plasmids carrying genes optimized by the gold standard (standard) or plasmids carrying genes optimized by tubulin III (novel). 3 days after transfection, flow cytometry (CytoFLEX, Beckman Coulter Life Sciences, Indianapolis, USA) was used to measure transfection efficiency. Cell pellets were collected 5 days after transfection for Western blotting to determine the expression level of the Lldr gene using antibodies labeled with c-myc.

[0194] The starting E. coli L1Dr sequence is represented by SEQ ID NO: 9:

[0195]

[0196]

[0197] The L1Dr sequence that was codon-optimized based on human codon usage frequency is represented by SEQ ID NO: 10:

[0198]

[0199] The LlDr sequence codon-optimized using the codon bias of tubulin III is represented by SEQ ID NO: 11, wherein the altered codons are highlighted in bold:

[0200]

[0201] result

[0202] No significant differences were identified in the transfection efficiency of the two plasmids in iPSCs and HEK293 cells ( Fig.24 A). Western blot demonstrated that the novel optimization method based on codon bias of tubulin III resulted in increased expression of LIDr compared to the standard gold standard optimization method in both iPSCs and HEK293 cells ( Fig.24 B and Fig.24 C).

[0203] In both HEK293 cells and iPSCs, L1dr gene expression was robustly increased by a (novel) codon optimization approach based on tubulin III codon bias. These experiments demonstrate that this novel codon optimization approach is beneficial for promoting and protecting target gene expression in iPSC-derived cell types and is ideally suited for modulating gene expression in target cell types.

[0204] These results demonstrate that the codon optimization approach described herein circumvents gene silencing throughout iPSC differentiation and also promotes transcription and translation of target genes in desired cell types.

[0205] Materials and Methods

[0206] Construct

[0207] All constructs were designed on a backbone generated by Metzakopian et al. Sci Rep. [Scientific Report] 201722; 7(1): 2244. These constructs have both PiggyBac inverted terminal repeats to enable transposase-mediated genomic integration (PB transposon) and HIV-1 long terminal repeats to allow lentiviral genomic integration (pKLV-PB-backbone). Presynthesized gene blocks (IDT) were used to generate any novel constructs, which were integrated into the backbone using Gibson assembly. The three Cas9 variants used were driven by the EF1A promoter and had blasticidin antibiotic resistance. Genome-locus targeting constructs were generated using Gibson assembly from PCR fragments amplified from existing plasmids / extracted genomic DNA. Schematic diagrams of each construct generated and used in this work are provided in the accompanying drawings. When stable integration by transposition of the transgene is desired, a plasmid encoding the piggyBac transposase (HyPBase (Yusa et al. PNAS [Proceedings of the National Academy of Sciences of the United States of America] 2011108(4):1531-1536)) is co-transfected.

[0208] Cell culture

[0209] Unless otherwise mentioned, all materials and plasticware used for routine cell culture purposes were obtained from Sigma.

[0210] HEK293 cells

[0211] HEK293 cells were routinely cultured in Dulbecco's modified basal medium (Gibco) supplemented with penicillin (100 U / ml), streptomycin (100 μg / ml), L-glutamine (2 mM) and 15% fetal bovine serum. When 70% confluence was reached, cells were regularly detached using trypsin-EDTA solution (Sigma), and 1 / 10 of the population was reseeded into a new culture dish.

[0212] Bob-iNgn2-opti-ox IPS cells

[0213] TRE-inducible Ngn2-driven Bob iPS cells were a kind gift from Dr. Mark Kotter. Bob-iNgn2-iPSCs were cultured and maintained according to established protocols (Pawlowski et al. Stem Cell Reports 20178(4):803-812). In brief, iPS cells were maintained in TeSR E8 complete medium (Stem Cell) with supplements on vitronectin-coated plates. After reaching 70% confluence, iPSCs were allowed to separate using a 0.5 mM EDTA solution in PBS. After incubation for 5 min, the cells were ground and re-seeded (1 / 4 to 1 / 6). When gene targeting / transfection was required, Accutase (Stem Cell) was used to make the cells into a single cell suspension for 5 min. The suspended cells were centrifuged, counted and re-seeded in E8 medium (with Rock inhibitor) on a vitronectin-coated plate according to the required number.

[0214] Bob-iNgn2-optio-ox differentiates into cortical neurons

[0215] To induce cortical neuron differentiation, iPSCs were made into single-cell suspensions and plated at 25k cells / cm 2The density of 100 μg / ml was inoculated on the plate coated with geltrex. On the second day, the cell received differentiation medium for 2 consecutive days, which included DMEM / F 12 (Gibco), N2 supplement (1X), L-glutamine (1X), non-essential amino acid (1X), 2-mercaptoethanol (5uM), penicillin-streptomycin (1X) and doxycycline (1ug / ml). From the 3rd day, the cell received differentiation medium, which included neuron basal medium (Neurobasal) (Gibco), B27 supplement (1X), L-glutamine (1X), 2-mercaptoethanol (5uM), penicillin-streptomycin (1X), doxycycline (1ug / ml), NT3 (4pg / ml) and BDNF (100pg / ml). The culture medium was changed every day until the 6th day of differentiation, and thereafter the culture medium was changed every other day until the end of the experiment.

[0216] Mantle virus production

[0217] Lentivirus was produced in the HEK293FT cell line using the ViraPower Lentivirus Expression System (Invitrogen) according to the manufacturer's instructions, or using the lentiviral packaging plasmid psPAX2 (Addgene, plasmid #12260) and the pMD2.G envelope plasmid containing VSV-G (Addgene, plasmid #12259) as described in (Dull et al. J Virol 1998; Cribbs et al. BMC Biotechnol 2013). HEK293 FT cells were cultured in DMEM supplemented with 10% FBS (Gibco) and grown on 0.02% gelatin (Sigma) coated plates. Virus production was performed in Opti-Mem (Gibco) using established protocols. Virus from the culture medium was harvested 3 days after transfection. The supernatant was passed through a 45uM PVDF filter, after which the virus was pelleted by centrifugation at 6000 g for 18h at 4°C. The next day, the virus pellet was dissolved in PBS, aliquoted and stored at -80°C.

[0218] Plasmid transfection

[0219] HEK293 cells and Bob-iNgn2-iPS cells were grown to 70% confluence in 6-well plates. Cells were detached with trypsin / EDTA or Accutase, respectively, and resuspended in culture medium for reverse transfection (approximately 1×10 cells / mL in 250 μl per transfection). 6Cells were transfected with 200 ng of PiggyBac transposase and 1000 ng of Cas9 construct. HEK293 cells were transfected with Lipofectamine LTX (Invitrogen) or Bob-iNgn2-iPSCs were transfected with Lipofectamine-STEM (Invitrogen) according to the manufacturer's instructions. The medium was changed after 24 h. Stably transfected cell lines were generated by selection with blasticidin (10 μg / ml) for at least 10 days after transfection. In the case of transfection of gRNA plasmids or reporter plasmids, selection of these plasmids was omitted.

[0220] Mantle virus transduction

[0221] All transductions were performed on single cell suspension cells in medium containing lentivirus and polybrene (4 ug / ml) (Sigma) at 37° C. Cells were incubated overnight at 37° C. and the medium was changed the next day.

[0222] Flow cytometric analysis

[0223] All cells including untransfected controls were harvested at regular time intervals (mainly day 4 and day 7 after transfection) and analyzed for BFP / GFP fluorescence in a flow cytometer (CytoFLEX, Beckman Coulter Life Sciences, Indianapolis, IN, USA).

[0224] Codon optimization

[0225] Cas9 was codon optimized to reflect the codon usage of a neuronal pan-marker (Tubulin III). Codon usage analysis was performed for Cas9, Cas12a, and Cas13Rx using a tool available at https: / / www.biologicscorp.com / tools / CodonUsageCalculator / .

[0226] The codons of the target nucleic acid sequence (Cas9 / Cas12a / Cas13Rx) are manually checked and changed to the preferred codons of the reference nucleic acid sequence (tubulin III) when necessary. Codons are preferentially changed to highly preferred codons for each amino acid. When multiple codons are to be changed within a sequence of 60 bases, an attempt is made to achieve a distribution reflecting the codons in the reference sequence. The distribution of nucleotides A, T, G, and C per 300 bases is also considered, because sequences with a GC content of >60% may be difficult to synthesize. Therefore, for amino acids encoded by 3 or more synonymous codons, codons rich in A and T are introduced when necessary and applicable.

[0227] Western blotting

[0228] During different time points of the experiment, cell lysates from HEK293 cells or Bob-iNgn2-iPSCs and neurons were collected after PBS washing. Whole cell proteins were extracted using RIPA buffer (Sigma) supplemented with 1X PIC. The amount of protein was determined using the Bradford assay, and 30 μg of lysate was diluted in 4%-15% TGX TM Electrophoresis was performed on a precast protein gel (Biorad). Proteins were transferred to a PVDF membrane (Millipore) using a Turboblot system (Biorad). The transferred proteins were then immunoblotted against Cas9 ((7A9-3A3) mouse mAb #14697, dilution 1:800) and Gapdh (Sigma, #G8795, dilution 1:4000).

[0229] Quantitative RT-PCR (RT-q PCR)

[0230] Total RNA was extracted using RNeasy micro kit (Qiagen) according to the manufacturer's instructions. First-strand cDNA was synthesized using qScript cDNA supermix (Quantabio) according to the manufacturer's protocol. All qPCR studies were performed using Sybr green primers designed for amplifying the CDS of the target gene. qPCR was run on QuantStudio real-time PCR system (Applied Biosystems). For both the target gene and housekeeping gene (18S RNA), samples from 3 independent experiments were run in triplicate. Expression levels were normalized relative to 18sRNA.

[0231] Graphical representation

[0232] All graphical representations were generated using GraphPad Prism 7 software.

[0233] SEQ ID NO:8—Ensemb1 transcript TUBB3-208ENST00000555576.5:

[0234]

[0235]

Claims

1. A method for codon-optimizing a target nucleic acid sequence for expression in a host cell, the method comprising changing the codon usage frequency of the target nucleic acid sequence based on the codon usage frequency of a gene encoding a protein that is highly expressed in the host cell or the codon usage frequency of a gene encoding a protein that is highly expressed in cells from the same species as the host cell.

2. The method of claim 1, wherein the method comprises replacing one or more non-preferred codons in the target nucleic acid sequence with preferred synonymous codons, wherein: (a) the non-preferred codon is a codon used at a low frequency in the gene encoding the highly expressed protein; and (b) Preferred codons are codons used at a high frequency in the gene encoding the highly expressed protein.

3. The method of claim 2, wherein a non-preferred codon is a codon used by the gene encoding the highly expressed protein at a lower frequency than would be expected if each synonymous codon were used randomly.

4. The method of claim 2 or claim 3, wherein the gene encoding the highly expressed protein uses non-preferred codons at a frequency of less than 50%, less than 45%, less than 40%, less than 35%, less than 33%, less than 30%, less than 25%, less than 20%, less than 16%, less than 15%, less than 10%, less than 5% or 0%.

5. The method of any one of claims 2 to 4, wherein the preferred codon is a codon that is used by the gene encoding the highly expressed protein at a higher frequency than would be expected if each synonymous codon were used randomly.

6. The method of any one of claims 2-5, wherein the gene encoding the highly expressed protein uses preferred codons at a frequency of at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or 100%.

7. The method of any one of claims 2-6, wherein the method comprises replacing at least 25%, at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or 100% of the non-preferred codons in the target nucleic acid with preferred synonymous codons.

8. The method of any one of claims 2-7, wherein the method comprises replacing all non-preferred codons used at a frequency of 0% by the gene encoding the highly expressed protein within the target nucleic acid with preferred synonymous codons.

9. The method of any one of claims 2 to 8, wherein the method comprises replacing all non-preferred codons with preferred synonymous codons in the region of the N-terminal region encoding a protein of the target nucleic acid.

10. The method of claim 9, wherein the method comprises replacing all non-preferred codons with preferred synonymous codons in the 5' region of the target nucleic acid, optionally in the first at least 100, at least 200, at least 300, at least 400, at least 500, at least 600, at least 700, at least 800, at least 900 or at least 1000 codons starting from the 5' end of the target nucleic acid.

11. The method of any preceding claim, wherein the highly expressed protein is a housekeeping protein or a cell marker protein.

12. The method of claim 11, wherein the highly expressed protein is selected from the group consisting of GAPDH, β-tubulin, β-actin and tubulin III.

13. The method of claim 12, wherein the highly expressed protein is tubulin III.

14. The method of claim 13, wherein the one or more non-preferred codons are selected from: alanine codons GCA, GCG and GCT; arginine codons AGA and CGT; cysteine ​​codon TGT; glutamine codon CAA; isoleucine codon ATA; leucine codons CTA and TTA; lysine codon AAA; proline codon CCG; serine codon TCC; threonine codons ACA, ACG and ACT; tyrosine codon TAT; valine codons GTA and GTT; and stop codons TAA and TAG.

15. The method of claim 13 or claim 14, wherein the one or more non-preferred codons are selected from: asparagine codon AAT; aspartate codon GAT; glutamate codon GAA; glycine codons GGA, GGG and GGT; histidine codon CAC; isoleucine codon ATT; leucine codons CTC, CTT and TTG; phenylalanine codon TTT; proline codon CCA; serine codons TCA and TCG; and valine codon GTC.

16. The method of any one of claims 13-15, wherein the preferred codon is selected from: alanine codon GCC; cysteine ​​codon TGC; glutamine codon CAG; lysine codon AAG; threonine codon ACC; tyrosine codon TAC; and stop codon TGA.

17. The method of any one of claims 13-16, wherein the preferred codons are selected from: arginine codons AGG, CGA, CGC and CGG; asparagine codon AAC; aspartic acid codon GAC; glutamate codon GAG; glycine codon GGC; histidine codon CAT; isoleucine codon ATC; leucine codon CTG; phenylalanine codon TTC; proline codons CCC and CCT; serine codons AGC, AGT and TCT; and valine codon GTG.

18. The method of any preceding claim, wherein the host cell is selected from the group consisting of a human cell, a bacterial cell, a yeast cell and a fungal cell.

19. The method of claim 18, wherein the host cell is a human cell.

20. The method of claim 19, wherein the host cell is a HEK293 cell.

21. The method of claim 19, wherein the host cell is a human induced pluripotent stem cell (iPSC).

22. The method of any one of claims 19-21, wherein the host cell is a differentiated cell derived from iPSC, optionally wherein the host cell is selected from iPSC-derived neurons such as cortical neurons, dopaminergic neurons or motor neurons, iPSC-derived macrophages, iPSC-derived cardiomyocytes, and iPSC-derived hepatocytes.

23. A method as claimed in any preceding claim, wherein the target nucleic acid encodes a Cas protein, optionally wherein the Cas protein is selected from Cas9, Cas12a and Cas 13Rx.

24. A nucleic acid comprising a nucleic acid sequence that has been codon-optimized by the method of any one of claims 1 to 23.

25. A codon-optimized nucleic acid for improved expression in a host cell, wherein the codon usage frequency of the nucleic acid corresponds to the codon usage frequency of a gene encoding a protein that is highly expressed by the host cell or the codon usage frequency of a gene encoding a protein that is highly expressed in cells from the same species as the host cell.

26. The codon-optimized nucleic acid of claim 25, wherein the codon-optimized nucleic acid comprises a lower frequency of non-preferred codons compared to a non-optimized nucleic acid sequence encoding the same amino acid sequence.

27. The codon-optimized nucleic acid of claim 25 or claim 26, wherein the codon-optimized nucleic acid comprises a higher frequency of preferred codons compared to a non-optimized nucleic acid sequence encoding the same amino acid sequence.

28. A nucleic acid encoding Cas9 and comprising a nucleic acid sequence having at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or 100% sequence identity to SEQ ID NO: 1 or SEQ ID NO:

3.

29. A nucleic acid encoding Cas12a and comprising a nucleic acid sequence having at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or 100% sequence identity to SEQ ID NO:

4.

30. A nucleic acid encoding Cas13Rx and comprising a nucleic acid sequence having at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or 100% sequence identity to SEQ ID NO:

5.

31. A vector comprising the nucleic acid of any one of claims 24-30.

32. A host cell comprising the nucleic acid of any one of claims 24-30 or the vector of claim 31.

33. A codon-optimized nucleic acid sequence as described in any one of claims 24-27 or a host cell comprising the nucleic acid as described in claim 32, wherein the host cell is selected from human cells, bacterial cells, yeast cells and fungal cells.

34. The method of claim 33, wherein the host cell is a human cell.

35. The method of claim 34, wherein the host cell is a HEK293 cell.

36. The method of claim 34, wherein the host cell is a human induced pluripotent stem cell (iPSC).

37. The method of any one of claims 33-36, wherein the host cell is a differentiated cell derived from iPSC, optionally wherein the host cell is selected from iPSC-derived neurons such as cortical neurons, dopaminergic neurons or motor neurons, iPSC-derived macrophages, iPSC-derived cardiomyocytes, and iPSC-derived hepatocytes.